Cbfβ: A key regulator in skeletal stem cell differentiation, bone development, and disease
Open Access
- 25 February 2025
- journal article
- review article
- Published by Wiley in The FASEB Journal
- Vol. 39 (4) , e70399
Abstract
The skeletal system comprises closely related yet functionally distinct bone and cartilage tissues, regulated by a complex network of transcriptional factors and signaling molecules. Among these, core‐binding factor subunit beta (Cbfβ) emerges as a critical co‐transcriptional factor that stabilizes Runx proteins, playing indispensable roles in skeletal development and homeostasis. Emerging evidence from genetic mouse models has highlighted the essential role of Cbfβ in directing the lineage commitment of mesenchymal stem cells (MSCs) and their differentiation into osteoblasts and chondrocytes. Notably, Cbfβ deficiency is strongly associated with severe skeletal dysplasia, affecting both endochondral and intramembranous ossification during embryonic and postnatal development. In this review, we synthesize recent advancements in understanding the structural and molecular functions of Cbfβ, with a particular focus on its interactions with key signaling pathways, including BMP/TGF‐β, Wnt/β‐catenin, Hippo/YAP, and IHH/PTHrP. These pathways converge on the Cbfβ/RUNX2 complex, which orchestrates a gene expression program essential for osteogenesis, bone formation, and cartilage development. The integration of these signaling networks ensures the precise regulation of skeletal development, remodeling, and repair. Furthermore, the successful local delivery of Cbfβ to address bone abnormalities underscores its potential as a novel therapeutic target for skeletal disorders such as cleidocranial dysplasia, osteoarthritis, and bone metastases. By elucidating the molecular mechanisms underlying Cbfβ function and its interactions with key signaling pathways, these insights not only advance our understanding of skeletal biology but also offer promising avenues for clinical intervention, ultimately improving outcomes for patients with skeletal disorders.Keywords
Funding Information
- National Natural Science Foundation of China (81400489)
This publication has 196 references indexed in Scilit:
- A Bone Targeting Nanoparticle Loaded OGP to Restore Bone Homeostasis for Osteoporosis TherapyAdvanced Healthcare Materials, 2023
- The relevance of the hematopoietic niche for therapy resistance in acute myeloid leukemiaInternational Journal of Cancer, 2023
- Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2023
- Specific and spatial labeling of P0‐Cre versus Wnt1‐Cre in cranial neural crest in early mouse embryosGenesis, 2017
- Cbfb Regulates Bone Development by Stabilizing Runx Family ProteinsJournal of Bone and Mineral Research, 2014
- Core Binding Factor Beta (Cbfβ) Controls the Balance of Chondrocyte Proliferation and Differentiation by Upregulating Indian hedgehog (Ihh) Expression and Inhibiting Parathyroid Hormone-Related Protein Receptor (PPR) Expression in Postnatal Cartilage and Bone FormationJournal of Bone and Mineral Research, 2014
- Fracture healing is accelerated in the absence of the adaptive immune systemJournal of Bone and Mineral Research, 2010
- Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasiaHuman Mutation, 2010
- Core binding factor beta (CBFB) haploinsufficiency due to an interstitial deletion at 16q21q22 resulting in delayed cranial ossification, cleft palate, congenital heart anomalies, and feeding difficulties but favorable outcomeAmerican Journal of Medical Genetics Part A, 2006
- Mutations in theRUNX2 gene in patients with cleidocranial dysplasiaHuman Mutation, 2002